EN DE
Watch Dare Bioscience Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Dare Bioscience Inc (DARE) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Dare Bioscience Inc stock $0.51, price $0.69, that is 26.0% below the price, quality 35 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

DB Dare Bioscience Inc logo Thin data Nov 10, 2026

Dare Bioscience Inc

DARE · US
Expensive, weak quality

Our calculation puts a fair price 26% below what the stock costs today.

Negative equity (buybacks among others)
Mixed vs. peers (2/5)
Fair value $0.5121 · Overvalued
Quality 35/100
Weak Growth (revenue 3y −53.1 %/yr in USD)
Negative free cash flow
Narrow moat 21/100 · thin data
Thin data
Estimate
Watch Dare Bioscience Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$25.56 $0.6240 Fair Value $0.5121 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $0.6240 – $25.56 · fair‑value band $0.3840 – $0.6401 · the $0.6921 price screens above the $0.5121 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow Dare Bioscience in your weekly email

Every Wednesday you see whether Dare Bioscience is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis.

Show moreShow less

It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies.

In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1 and DARE-PTB1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB2 for the prevention of preterm birth.

Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally.

Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.

Stock analysis

Dare Bioscience Inc (DARE) currently trades at $0.6921, while our estimate is $0.5121, 26% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $0.3840 (bear) to $0.6401 (bull), the price of $0.6921 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 35/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Dare Bioscience Inc reported revenue of $1.0M in FY2025 versus $10.0M in FY2021, a compound −43.3%/yr. Reported net income was −$13.4M in FY2025.

Key figures

Market cap $13.3M Micro · P/S ratio 8.99 · EPS (TTM) $−0.7100 · Return on equity −2,543% · Return on assets (EBIT) −87.0% (5-year average) · Operating margin −1,583% · Revenue (TTM) $1.4M · Revenue growth (YoY) +500%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 21 out of 100 (low confidence).

What moves the price

The share trades about 79% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −26%, DARE screens richer than that median.

Fair Value

Bear $0.3840 Fair Value $0.5121 Bull $0.6401
Price $0.6921 · Downside -26.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 35/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 73
Are margins and returns getting better?
Cashflow 5
Do the profits arrive as real cash?
Financial strength 48
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 25
How calm the share price moves, does not count
Price momentum 0
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 50
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 5 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−53.1%
Revenue growth 14 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−390.7% (2021) → −1,315.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

DARE screens overvalued: fair value 26% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Dare Bioscience Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 35 · Below median
Fair Value upside −26.0% · Above median
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −41.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 499.6% · Top 25%
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
P/S (12 months) 9.73× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 0
FUTURE (revenue growth)100 · sector 0
PAST (return on equity)0 · sector 0
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs DARE
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs DARE
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs DARE
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs DARE
argenx SE ARGX $971.55 $908.40 −7% vs DARE
CSL Limited CSL A$201.68 A$181.40 −10% vs DARE
Moderna, Inc MRNA $250.83 $158.70 −37% vs DARE
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs DARE
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs DARE
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs DARE

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Dare Bioscience Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Dare Bioscience Inc Fair Value". https://www.fairvalue-calculator.com/stock/DARE

Frequently asked questions

Is Dare Bioscience Inc (DARE) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $0.5121 versus a price of $0.6921, about 26% lower (overvalued).
What is the fair value of DARE?
Our estimate for Dare Bioscience Inc is $0.5121 (as of Nov 10, 2026), built from audited fundamentals. The current price: $0.6921.
What is the quality score of DARE?
Dare Bioscience Inc has a Quality Score of 35/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Dare Bioscience Inc (DARE)?
Our calculated price target is the estimate of $0.5121 (as of Nov 10, 2026). Cautious scenario $0.3840, optimistic scenario $0.6401. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Dare Bioscience Inc stock forecast for 2026?
Our estimate puts fair value at $0.5121, about 26% lower versus a price of $0.6921 (overvalued). Cautious scenario $0.3840, optimistic scenario $0.6401. The calculation is refreshed regularly with new filings.
What is the revenue of Dare Bioscience Inc (DARE)?
Dare Bioscience Inc reported trailing-twelve-month revenue of about $1.4M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of Dare Bioscience Inc (DARE)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Dare Bioscience Inc it is $0.5121 per share (as of Nov 10, 2026), against a price of $0.6921.
Is Dare Bioscience Inc stock overvalued or undervalued in 2026?
As of Nov 10, 2026, DARE trades above its calculated fair value: price $0.6921, fair value $0.5121, a gap of about −26% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DARE?
No. The price is what the market pays today ($0.6921); the fair value is what the company's own numbers justify ($0.5121). For Dare Bioscience Inc the two are $0.1800 per share apart. That gap is exactly why we show both numbers side by side.
How much is Dare Bioscience Inc worth?
The market values Dare Bioscience Inc at about $13.3M (market capitalisation, as of Nov 10, 2026). Per share that is $0.6921; our models calculate a fair value of $0.5121 per share.
What do the bullish and bearish scenarios say about DARE?
Our models span a range for Dare Bioscience Inc: cautious scenario $0.3840, base $0.5121, optimistic $0.6401 per share (as of Nov 10, 2026, price $0.6921). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Dare Bioscience Inc (DARE)?
Balance-sheet figures for Dare Bioscience Inc (as of Nov 10, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 35/100, which measures business quality independently of the share price.
How far is DARE from its 52-week high?
Dare Bioscience Inc trades at $0.6921, about 79% below its 52-week high of $3.27 and 11% above the low of $0.6240 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $0.5121 is for.
Which stocks are comparable to Dare Bioscience Inc?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Dare Bioscience Inc stock attractive at the current price?
The data as of Nov 10, 2026: price $0.6921, calculated fair value $0.5121 (−26%), Quality Score 35/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Dare Bioscience Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Dare Bioscience Inc (DARE)?
The closing price on Nov 10, 2026 was $0.6921. Our estimate is $0.5121, about 26% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Dare Bioscience Inc right now?
The price sits above even our optimistic bull case ($0.6401). The favourable scenario is already priced in. Weak quality (35/100) and above fair value at the same time, the margin of safety is missing on both counts. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of Dare Bioscience Inc

How large is the market capitalisation of Dare Bioscience Inc (DARE)?
The market capitalisation of Dare Bioscience Inc is $13.3M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Dare Bioscience Inc (DARE)?
The price-to-sales ratio of Dare Bioscience Inc is 8.99 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Dare Bioscience Inc (DARE)?
Earnings per share at Dare Bioscience Inc are $−0.7100. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Dare Bioscience Inc (DARE)?
The return on equity (ROE) of Dare Bioscience Inc is −2,543% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Dare Bioscience Inc (DARE)?
On an EBIT basis the return on assets of Dare Bioscience Inc is −87.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Dare Bioscience Inc (DARE)?
The operating margin of Dare Bioscience Inc is −1,583% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Dare Bioscience Inc (DARE)?
Revenue at Dare Bioscience Inc is growing +500% versus a year earlier (3y avg −53.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Dare Bioscience Inc (DARE) generate?
The free cash flow of Dare Bioscience Inc is −$10.3M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Dare Bioscience Inc (DARE) hold?
Dare Bioscience Inc holds more cash than debt, $22.1M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Dare Bioscience Inc in the live analysis

One click puts Dare Bioscience Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.